QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
NASDAQ:ALLO

Allogene Therapeutics - ALLO Stock Forecast, Price & News

$5.03
+0.01 (+0.20%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.96
$5.20
50-Day Range
$5.02
$8.21
52-Week Range
$4.91
$17.49
Volume
1.29 million shs
Average Volume
1.91 million shs
Market Capitalization
$726.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.69

Allogene Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.62 Rating Score
Upside/​Downside
251.7% Upside
$17.69 Price Target
Short Interest
Bearish
49.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.36mentions of Allogene Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$41,670 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.45) to ($2.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

424th out of 995 stocks

Biological Products, Except Diagnostic Industry

75th out of 166 stocks


ALLO stock logo

About Allogene Therapeutics (NASDAQ:ALLO) Stock

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Receive ALLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALLO Stock News Headlines

10 Analysts Have This to Say About Allogene Therapeutics
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
What 10 Analyst Ratings Have To Say About Allogene Therapeutics
Q4 2022 Allogene Therapeutics Inc Earnings Call
Perrigo (PRGO) Beats Q4 Earnings Estimates, Lags on Sales
JPMorgan’s Best Performing 15 Stock Picks for 2023
4 Biotech Stocks Set to Outpace Q4 Earnings Estimates
See More Headlines
Receive ALLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALLO Company Calendar

Last Earnings
2/28/2023
Today
3/27/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALLO
Fax
N/A
Employees
308
Year Founded
2018

Price Target and Rating

Average Stock Price Forecast
$17.69
High Stock Price Forecast
$31.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+251.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.62
Research Coverage
13 Analysts

Profitability

Net Income
$-332,630,000.00
Net Margins
-136,885.59%
Pretax Margin
-136,885.59%

Debt

Sales & Book Value

Annual Sales
$240,000.00
Book Value
$4.62 per share

Miscellaneous

Free Float
101,437,000
Market Cap
$726.84 million
Optionable
Not Optionable
Beta
0.81

Social Links


Key Executives

  • David D. Chang
    President, Chief Executive Officer & Director
  • Eric Schmidt
    Chief Financial Officer
  • Barbra Sasu
    Chief Scientific Officer
  • Alison Moore
    Chief Technical Officer
  • Arun Balakumaran
    Chief Medical Officer













ALLO Stock - Frequently Asked Questions

Should I buy or sell Allogene Therapeutics stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALLO shares.
View ALLO analyst ratings
or view top-rated stocks.

What is Allogene Therapeutics' stock price forecast for 2023?

13 brokers have issued 1 year price targets for Allogene Therapeutics' stock. Their ALLO share price forecasts range from $6.00 to $31.00. On average, they expect the company's stock price to reach $17.69 in the next year. This suggests a possible upside of 251.7% from the stock's current price.
View analysts price targets for ALLO
or view top-rated stocks among Wall Street analysts.

How have ALLO shares performed in 2023?

Allogene Therapeutics' stock was trading at $6.29 at the start of the year. Since then, ALLO shares have decreased by 20.0% and is now trading at $5.03.
View the best growth stocks for 2023 here
.

Are investors shorting Allogene Therapeutics?

Allogene Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 39,800,000 shares, an increase of 8.0% from the February 28th total of 36,860,000 shares. Based on an average daily trading volume, of 1,900,000 shares, the days-to-cover ratio is currently 20.9 days. Approximately 49.6% of the shares of the company are short sold.
View Allogene Therapeutics' Short Interest
.

When is Allogene Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our ALLO earnings forecast
.

How were Allogene Therapeutics' earnings last quarter?

Allogene Therapeutics, Inc. (NASDAQ:ALLO) posted its quarterly earnings data on Tuesday, February, 28th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.71) by $0.05. The company earned $0.05 million during the quarter, compared to analyst estimates of $0.06 million. Allogene Therapeutics had a negative trailing twelve-month return on equity of 43.44% and a negative net margin of 136,885.59%. The firm's quarterly revenue was down 6.0% on a year-over-year basis. During the same period last year, the company earned ($0.54) earnings per share.

What is David Chang's approval rating as Allogene Therapeutics' CEO?

2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Allogene Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

When did Allogene Therapeutics IPO?

(ALLO) raised $272 million in an initial public offering on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies served as the underwriters for the IPO.

What is Allogene Therapeutics' stock symbol?

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Who are Allogene Therapeutics' major shareholders?

Allogene Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (4.12%), JPMorgan Chase & Co. (2.61%), Millennium Management LLC (2.27%), Dimensional Fund Advisors LP (1.66%), Geode Capital Management LLC (1.18%) and Two Sigma Investments LP (1.12%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Owen N Witte, Owen N Witte, Rafael Amado and Veer Bhavnagri.
View institutional ownership trends
.

How do I buy shares of Allogene Therapeutics?

Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allogene Therapeutics' stock price today?

One share of ALLO stock can currently be purchased for approximately $5.03.

How much money does Allogene Therapeutics make?

Allogene Therapeutics (NASDAQ:ALLO) has a market capitalization of $726.84 million and generates $240,000.00 in revenue each year. The company earns $-332,630,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis.

How many employees does Allogene Therapeutics have?

The company employs 308 workers across the globe.

How can I contact Allogene Therapeutics?

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.allogene.com. The company can be reached via phone at (650) 457-2700 or via email at ir@allogene.com.

This page (NASDAQ:ALLO) was last updated on 3/27/2023 by MarketBeat.com Staff